These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24995794)

  • 1. Emerging drugs for osteoporosis.
    Feurer E; Chapurlat R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):385-95. PubMed ID: 24995794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate models for novel osteoporosis drug discovery and future perspectives.
    Gennari L; Rotatori S; Bianciardi S; Gonnelli S; Nuti R; Merlotti D
    Expert Opin Drug Discov; 2015; 10(11):1201-16. PubMed ID: 26292627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established and forthcoming drugs for the treatment of osteoporosis.
    Lems WF; Geusens P
    Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.
    Henriksen K; Thudium CS; Christiansen C; Karsdal MA
    Expert Opin Ther Targets; 2015; 19(11):1575-84. PubMed ID: 25960169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging anabolic agents in the treatment of osteoporosis.
    Lovato C; Lewiecki EM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of drug development for the prevention and treatment of osteoporosis.
    Schwarz P; Jørgensen NR; Abrahamsen B
    Expert Opin Drug Discov; 2014 Mar; 9(3):245-53. PubMed ID: 24490672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging anabolic treatments in osteoporosis.
    Mosekilde L; Tørring O; Rejnmark L
    Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.
    Estell EG; Rosen CJ
    Nat Rev Endocrinol; 2021 Jan; 17(1):31-46. PubMed ID: 33149262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of osteoporosis treatment - a research update.
    Lippuner K
    Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE; Baden M; Lems WF
    Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
    Lyritis GP; Georgoulas T; Zafeiris CP
    Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the optimal use of bone forming agents in osteoporosis.
    Veronese N; Briot K; Guañabens N; Albergaria BH; Alokail M; Al-Daghri N; Bemden AB; Bruyère O; Burlet N; Cooper C; Curtis EM; Ebeling PR; Halbout P; Hesse E; Hiligsmann M; Camargos BM; Harvey NC; Perez AD; Radermecker RP; Reginster JY; Rizzoli R; Siggelkow H; Cortet B; Brandi ML
    Aging Clin Exp Res; 2024 Aug; 36(1):167. PubMed ID: 39120740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of osteoporosis medications on fracture healing.
    Hegde V; Jo JE; Andreopoulou P; Lane JM
    Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential new drug targets for osteoporosis.
    Deal C
    Nat Clin Pract Rheumatol; 2009 Jan; 5(1):20-7. PubMed ID: 19098925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bones, heart and the new anabolic agent romosozumab.
    Pazianas M
    Postgrad Med J; 2019 Oct; 95(1128):521-523. PubMed ID: 31422376
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of osteoporosis in rheumatoid arthritis patients.
    Hoes JN; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.